



*Press release*

*Stockholm, Oct 26, 2011*

## **Interim Report – January to September 2011**

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody<sup>®</sup> molecules and Albumod<sup>™</sup>, today issued its Interim Report covering the first nine months of 2011.

### **Financial Highlights**

- Revenue for the first nine months of 2011 was SEK 20.7 (20.3) million
- EBITDA for the period amounted to SEK -1.2 (-7.8) million while the net loss amounted to SEK -8.7 (-15.8) million
- Cash flow from current operations before changes in working capital for the period was SEK -0.3 (-6.6) million
- Loan conversion completed, resulting in 107 960 988 new shares (210 819 391 in total) increasing shareholders' equity by SEK 27.0 million.

### **Key Corporate Highlights**

- The first in human study with the HER2-binding Affibody imaging agent ABY-025 in breast cancer patients was concluded during the quarter. The study's principal investigator is Dr. Henrik Lindman, Uppsala University Hospital, and the study Sponsor is Prof. Jörgen Carlsson, Uppsala University, with support from the Swedish Cancer Society.
- During the third quarter Affibody and GE Healthcare, a division of the General Electric Company, expanded its relationship in the field of large-scale affinity purification.
- Furthermore, Ass. Prof. Fredrik Frejd was appointed VP Research to further strengthen the company's focus on biopharmaceuticals.

David Bejker CEO, said: *“This quarter we are especially proud of the fact that our first in human study with ABY-025 has been concluded and look forward to the San Antonio Breast Cancer Symposium in December where the study will be presented.”*

### **Enquiries**

David Bejker, CEO  
Johan Stuart CFO

+46 706 454 948  
+46 706 644 096

## **About Affibody**

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody<sup>®</sup> molecules and Albumod<sup>™</sup>.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod<sup>™</sup>, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: [www.affibody.com](http://www.affibody.com)



Gunnar Asplunds allé 24, SE-171 63 Solna, Sweden.  
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, [www.affibody.com](http://www.affibody.com)